Your browser is no longer supported. Please, upgrade your browser.
TBPH Theravance Biopharma, Inc. daily Stock Chart
TBPH [NASD]
Theravance Biopharma, Inc.
Index- P/E- EPS (ttm)-4.33 Insider Own6.00% Shs Outstand59.46M Perf Week-7.71%
Market Cap1.59B Forward P/E- EPS next Y-2.65 Insider Trans-0.03% Shs Float50.88M Perf Month-17.73%
Income-246.90M PEG- EPS next Q-1.05 Inst Own92.70% Short Float5.56% Perf Quarter3.70%
Sales87.90M P/S18.11 EPS this Y-6.50% Inst Trans26.19% Short Ratio8.35 Perf Half Y31.37%
Book/sh-2.66 P/B- EPS next Y34.20% ROA-50.60% Target Price31.57 Perf Year50.84%
Cash/sh7.73 P/C3.27 EPS next 5Y11.40% ROE140.70% 52W Range15.18 - 31.54 Perf YTD-2.47%
Dividend- P/FCF- EPS past 5Y10.60% ROI-106.70% 52W High-19.94% Beta1.52
Dividend %- Quick Ratio- Sales past 5Y44.40% Gross Margin- 52W Low66.34% ATR1.40
Employees316 Current Ratio5.40 Sales Q/Q275.50% Oper. Margin- RSI (14)42.50 Volatility4.81% 5.60%
OptionableYes Debt/Eq- EPS Q/Q-5.70% Profit Margin- Rel Volume1.33 Prev Close24.97
ShortableYes LT Debt/Eq- EarningsMay 06 AMC Payout- Avg Volume338.62K Price25.25
Recom2.30 SMA20-7.28% SMA50-2.11% SMA2009.79% Volume451,525 Change1.12%
May-13-20Initiated Cowen Outperform $42
Jan-08-20Reiterated H.C. Wainwright Buy $25 → $30
Nov-06-19Upgrade Robert W. Baird Underperform → Neutral $22 → $18
Oct-29-19Initiated H.C. Wainwright Buy $25
Mar-29-18Resumed Piper Jaffray Overweight $45
Aug-17-17Initiated Evercore ISI Outperform $45
Jun-16-17Initiated Cantor Fitzgerald Overweight $55
May-11-17Reiterated Needham Buy $40 → $45
Dec-21-16Initiated Needham Buy $40
Nov-03-16Initiated Piper Jaffray Overweight
Oct-12-16Downgrade Robert W. Baird Neutral → Underperform $19 → $24
Aug-03-16Downgrade BofA/Merrill Neutral → Underperform
Jun-20-16Reiterated Leerink Partners Outperform $26 → $29
Jun-20-16Initiated Guggenheim Buy $30
May-12-16Initiated Leerink Partners Outperform $26
May-05-16Downgrade BofA/Merrill Buy → Neutral
Feb-03-15Upgrade Robert W. Baird Underperform → Neutral $13 → $17
Aug-14-14Downgrade Robert W. Baird Neutral → Underperform $21
May-26-20 12:36AM  Edited Transcript of TBPH earnings conference call or presentation 6-May-20 9:00pm GMT Thomson Reuters StreetEvents
May-08-20 02:31PM  Theravance Biopharma Inc (TBPH) Q1 2020 Earnings Call Transcript Motley Fool
May-07-20 01:57PM  Theravance (TBPH) Q1 Earnings Miss, Revenues Beat Estimates Zacks
May-06-20 07:35PM  Theravance Biopharma (TBPH) Reports Q1 Loss, Tops Revenue Estimates Zacks
Apr-29-20 12:33PM  Will Theravance Biopharma (TBPH) Report Negative Earnings Next Week? What You Should Know Zacks
Apr-28-20 12:33PM  Will Theravance Biopharma (TBPH) Report Negative Q1 Earnings? What You Should Know Zacks
10:35AM  Here's What We Think About Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Pay Simply Wall St.
06:00AM  Theravance Biopharma to Report First Quarter 2020 Financial Results on May 6, 2020 PR Newswire
Apr-23-20 06:00AM  Theravance Biopharma Announces First Subject Dosed in Phase 1 Study of TD-0903, in Development for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19 PR Newswire
Apr-20-20 06:00AM  Theravance Biopharma Announces Peer-Reviewed Publication Highlighting TD-1473 Program in the Journal of Crohn's and Colitis PR Newswire
Apr-14-20 04:41PM  Seth Klarman Dials Down Akebia Therapeutics Stake GuruFocus.com
Apr-09-20 07:00AM  Theravance Biopharma Responds to COVID-19 Pandemic by Advancing TD-0903 to Treat Hospitalized Patients with Acute Lung Injury PR Newswire +5.11%
Mar-25-20 11:30AM  Theravance Bio (TBPH) Up 2.1% Since Last Earnings Report: Can It Continue? Zacks -5.40%
Mar-23-20 06:32PM  Stocks To Watch: Theravance Biopharma Sees Relative Strength Rating Jump To 94 Investor's Business Daily
Mar-20-20 08:02PM  Seth Klarman Sees Bargains as the Market Heads Further Into Chaos GuruFocus.com
Mar-02-20 07:00AM  Theravance Biopharma Announces Closing of Private Placement of $400 Million Non-Recourse Notes PR Newswire
Feb-27-20 02:49PM  Analysts Have Lowered Expectations For Theravance Biopharma, Inc. After Its Latest Results Simply Wall St.
Feb-25-20 02:53PM  Theravance (TBPH) Q4 Earnings Miss, Revenues Beat Estimates Zacks
02:06AM  Edited Transcript of TBPH earnings conference call or presentation 24-Feb-20 10:00pm GMT Thomson Reuters StreetEvents
Feb-24-20 06:15PM  Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates Zacks -8.77%
Feb-18-20 07:00AM  Theravance Biopharma Announces Presentations at Upcoming Investor Conferences PR Newswire
Feb-17-20 12:30PM  Analysts Estimate Theravance Biopharma (TBPH) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-11-20 11:05PM  Theravance Biopharma Announces Pricing of Public Offering of Ordinary Shares PR Newswire -8.80%
02:21PM  How Does Investing In Theravance Biopharma, Inc. (NASDAQ:TBPH) Impact The Volatility Of Your Portfolio? Simply Wall St.
Feb-05-20 10:27AM  Theravance Pipeline Strong, Dependence on Yupelri a Concern Zacks
Jan-19-20 09:13AM  3 Strong Buy Biotech Stocks That Can Inject a Healthy Dose of Upside TipRanks
Jan-07-20 04:48PM  Theravance Biopharma Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-24-19 09:16AM  AstraZeneca's Triple-Combo COPD Inhaler Gets China's Nod Zacks
Dec-23-19 08:15AM  Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program PR Newswire
Dec-22-19 11:10AM  Hedge Funds Have Never Been Less Bullish On Theravance Biopharma Inc (TBPH) Insider Monkey
Dec-10-19 12:22PM  Seth Klarman Pares Paratek Pharmaceuticals Stake GuruFocus.com
Dec-05-19 11:31AM  Theravance Bio (TBPH) Up 25.6% Since Last Earnings Report: Can It Continue? Zacks
Dec-03-19 07:50AM  Theravance Biopharma Announces Dosing of First Patient in Phase 2 Allergen Challenge Study of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases PR Newswire
Nov-26-19 04:15PM  Theravance Biopharma to Present at Two Upcoming Investor Conferences PR Newswire
Nov-09-19 10:43AM  Edited Transcript of TBPH earnings conference call or presentation 5-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-06-19 04:30PM  Theravance Biopharma to Present at the 2019 Credit Suisse Healthcare Conference PR Newswire
11:19AM  Theravance (TBPH) Q3 Loss In Line, Revenues Lag Estimates Zacks
Nov-05-19 06:35PM  Theravance Biopharma (TBPH) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:05PM  Theravance Biopharma, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update PR Newswire
11:24AM  What's in Store for Cumberland Pharma (CPIX) in Q3 Earnings? Zacks
Oct-29-19 04:15PM  Theravance Biopharma to Report Third Quarter 2019 Financial Results on November 5 PR Newswire
10:32AM  Theravance Biopharma (TBPH) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
Oct-28-19 05:49PM  Here is What Hedge Funds Think About Theravance Biopharma Inc (TBPH) Insider Monkey
Oct-21-19 04:00PM  Theravance Biopharma and Mylan to Present New Data on YUPELRI® (revefenacin) at the 2019 CHEST Annual Meeting PR Newswire
Oct-07-19 10:25AM  Theravance Pipeline Strong, Dependence on Yupelri a Concern Zacks
Oct-02-19 01:34PM  Have Insiders Been Selling Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares? Simply Wall St.
07:05AM  AstraZeneca's Triple-Combo COPD Inhaler Gets CRL From FDA Zacks
Sep-25-19 04:05PM  Theravance Biopharma to Present at the 2019 Cantor Global Healthcare Conference PR Newswire
Sep-23-19 01:16PM  Seth Klarman Further Increases Translate Bio Stake GuruFocus.com
Sep-10-19 01:58PM  Baupost's Seth Klarman Dives Further Into Translate Bio GuruFocus.com +8.88%
11:46AM  Theravance Announces Positive Early Data on JAK Inhibitor Zacks
Sep-09-19 07:05AM  Theravance Biopharma Reports Positive Results from Phase 1 Clinical Trial of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases PR Newswire
Aug-28-19 04:30PM  Theravance Biopharma to Present at Two Upcoming Investor Conferences PR Newswire
Aug-12-19 10:47AM  Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises Zacks
Aug-11-19 08:32AM  How Theravance Biopharma, Inc. (NASDAQ:TBPH) Can Impact Your Portfolio Volatility Simply Wall St.
Aug-09-19 08:24AM  Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil Zacks
08:06AM  Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat Zacks
Aug-07-19 11:20AM  Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates Zacks
Aug-05-19 09:18AM  Corcept's (CORT) Earnings & Revenues Miss Estimates in Q2 Zacks
Aug-02-19 05:44PM  Edited Transcript of TBPH earnings conference call or presentation 31-Jul-19 12:00pm GMT Thomson Reuters StreetEvents
Aug-01-19 03:37PM  Theravance (TBPH) Q2 Loss Narrower, Revenues Beat Estimates Zacks
Jul-31-19 03:27PM  Theravance Biopharma, Inc. (TBPH) Q2 2019 Earnings Call Transcript Motley Fool
08:35AM  Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:05AM  Theravance Biopharma, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update PR Newswire
Jul-22-19 08:05AM  Theravance Biopharma Reports New Data from Phase 2 Study of Ampreloxetine (TD-9855) in Oral Presentation at 32nd European Neurology Congress PR Newswire
Jul-18-19 02:33PM  New antibiotics desperately needed for rising tide of drug-resistant superbugs American City Business Journals
Jun-27-19 11:27AM  How Much Did Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Pocket Last Year? Simply Wall St.
Jun-25-19 07:42AM  Drug maker stocks rally after AbbVie's deal to buy Allergan for 45% premium MarketWatch
Jun-20-19 09:18AM  AstraZeneca's Triple-Combo COPD Inhaler Gets Japan's Nod Zacks
Jun-18-19 09:00AM  Theravance Biopharma Reports New Data from Phase 2 Study of Ampreloxetine (TD-9855) in Presentation at 2019 International Association of Parkinsonism and Related Disorders (IAPRD) World Congress PR Newswire
Jun-17-19 03:31PM  Introducing Theravance Biopharma (NASDAQ:TBPH), The Stock That Slid 54% In The Last Five Years Simply Wall St.
Jun-15-19 12:38PM  The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs Benzinga
Jun-14-19 08:05AM  Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories PR Newswire
Jun-06-19 09:31AM  Theravance Bio (TBPH) Down 27.7% Since Last Earnings Report: Can It Rebound? Zacks
Jun-04-19 08:30AM  Theravance Biopharma Appoints Andrew Hindman as Senior Vice President and Chief Financial Officer PR Newswire
May-22-19 09:50AM  Lilly's Crohn's Disease Candidate Meets Phase II Study Goals Zacks
May-21-19 07:01AM  Theravance Biopharma Reports Data from Phase 1b Study of TD-1473 in Oral Presentation at Digestive Disease Week (DDW) 2019 PR Newswire
May-20-19 10:15AM  Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference PR Newswire
May-14-19 11:39PM  Theravance Biopharma Inc. (TBPH) Q1 2019 Earnings Call Transcript Motley Fool
02:21PM  Edited Transcript of TBPH earnings conference call or presentation 7-May-19 9:00pm GMT Thomson Reuters StreetEvents
08:30AM  Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 to be Featured in Oral Presentation at Digestive Disease Week (DDW) 2019 PR Newswire
May-08-19 11:44AM  Theravance (TBPH) Q1 Loss Widens, Revenues Miss Estimates Zacks -9.49%
May-07-19 07:15PM  Theravance Biopharma (TBPH) Reports Q1 Loss, Lags Revenue Estimates Zacks
06:12PM  Theravance Bio: 1Q Earnings Snapshot Associated Press
04:05PM  Theravance Biopharma, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update PR Newswire
May-02-19 01:20PM  Heres What Hedge Funds Think About Theravance Biopharma Inc (TBPH) Insider Monkey +6.52%
Apr-30-19 04:05PM  Theravance Biopharma to Report First Quarter 2019 Financial Results on May 7 PR Newswire
Apr-24-19 08:56AM  Read This Before Buying Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Simply Wall St.
Apr-02-19 08:30AM  Theravance Biopharma to Present at the 18th Annual Needham Healthcare Conference PR Newswire
Mar-28-19 09:30AM  Why Is Theravance Bio (TBPH) Down 7.9% Since Last Earnings Report? Zacks
Mar-25-19 08:30AM  Theravance Biopharma Announces Ampreloxetine (TD-9855) Phase 2 Study Results Selected for Oral Presentation at 32nd European Neurology Congress PR Newswire
Mar-13-19 02:27PM  Theravance (TBPH) Starts Dosing in Ulcerative Colitis Study Zacks +5.17%
Mar-12-19 08:30AM  Theravance Biopharma Announces First Patient Dosed in Phase 2b/3 Study of TD-1473 in Patients with Ulcerative Colitis PR Newswire
Mar-07-19 12:45PM  Edited Transcript of TBPH earnings conference call or presentation 26-Feb-19 10:00pm GMT Thomson Reuters StreetEvents
Feb-27-19 12:48PM  Theravance (TBPH) Q4 Loss Narrows, Revenues Beat Estimates Zacks
Feb-26-19 09:35PM  Theravance Biopharma Inc (TBPH) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:05PM  Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update PR Newswire
03:00PM  Theravance Biopharma Inc to Host Earnings Call ACCESSWIRE
Feb-21-19 08:30AM  Theravance Biopharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference PR Newswire -6.22%
07:45AM  Frontier Communications' (FTR) Q4 Earnings: What's in Store? Zacks
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease. Its product portfolio also include TD-1473, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY ELLIPTA for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Mylan Ireland Limited, Janssen Biotech, Inc., Alfasigma S.p.A, Trek Therapeutics, PBC, and Takeda Pharmaceutical Company Limited. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SABESAN VIJAYSVP, Technical OperationsDec 12Sale21.031,02721,598145,253Dec 16 06:09 PM